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Abstract The effect of estramustine and estramustine phos-
phate (EP) on the interaction of microtubule associated protein 2 
(MAP2) with actin has been examined. We show that (a) neither 
estramustine nor EP influences actin polymerisation (b) EP, but 
not estramustine, reduces the amount of MAP2 which co-
sediments with F-actin in a dose-dependent manner and (c) EP 
decreases the MAP2-induced crosslinking of F-actin into gelled 
networks. The data suggest, that unlike estramustine, EP 
interacts with MAP2 and modifies its interaction not only with 
microtubules but also with actin filaments. 
© 1997 Federation of European Biochemical Societies. 
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works [11], and the association of the protein with microtu-
bules [17]. 
MAP2 has also been shown to possess five to six EP-bind-
ing sites residing in the positively charged tubulin binding 
domain [18]. It is therefore possible that the introduction of 
additional charge from the phosphate moiety of EP could 
weaken the MAP:tubulin interaction and cause microtubule 
depolymerisation, an effect similar to that described for phos-
phorylation [15,17]. 
In view of the potential interaction of estramustine with 
tubulin and of an additional interaction of EP with MAPs, 
it is difficult to understand fully the mechanism of action of 
EP. We studied the effect of estramustine and EP on MAP 
interaction with actin with the aim of elucidating the differ-
ences in the mode of action of these two compounds. 
1. Introduction 2. Materials and methods 
Estramustine, an antineoplastic drug used in the treatment 
of prostatic carcinoma, is clinically administered as the phos-
phorylated analogue estramustine phosphate (EP) which is 
subsequently dephosphorylated in the cellular compartment 
[1]. Evidence has been presented both in vivo and in vitro 
suggesting that estramustine acts as an antimitotic drug by 
binding either to tubulin [2,3] or to MAPs [4,5]. In vivo es-
tramustine causes an abnormal pattern of microtubule com-
plexes and an alteration of the assembly/disassembly equilib-
rium only at high drug concentrations [6] or on long exposure 
[5], while in vitro it has been suggested to affect MAP-binding 
[4,5] or alternatively to show no effect on microtubule poly-
merisation [7]. On the other hand, EP interacts with MAPs 
and possesses antimicrotubule activity both in vitro [8] and in 
vivo [9,10]. 
MAP2 has been shown to interact with both microtubules 
and actin filaments [11-13] and to crosslink actin filaments, 
consequently possessing two or more actin binding sites [11-
13]. At least one of the actin binding sites resides in the C-
terminal domain containing the microtubule binding site [14]. 
This domain is known to be multiply phosphorylated [15,16] 
and although the phosphorylation does not affect MAP2: ac-
tin interaction it reduces the extension of actin filament net-
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The following buffer was used for all experiments described below: 
MES buffer (MES, 0.1 M; EGTA, 2.5 mM; MgCl2, 0.5 mM; EDTA; 
0.1 mM; pH 6.4 with NaOH). All biochemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO) and all chemicals were of Analar 
grade. 
2.1. Protein purification and composition 
Twice cycled calf brain microtubule protein was prepared according 
to Pedrotti and Islam [19]. Rabbit skeletal muscle actin and MAP2 
were purified as described by Pedrotti et al. [20]. 
Protein concentration was determined using Bio-Rad (Rockville 
Centre, NY) protein reagent and bovine serum albumin used as stand-
ard. SDS-PAGE was performed using the 'Phast System' (Pharmacia, 
Piscataway, NJ) and gels were stained with Coomassie blue R-250 
[19]. 
2.2. Assay procedures 
G-Actin (2 mg/ml) was polymerised in MES buffer containing 2 mM 
MgCL. at 37°C for 25 min. After polymerisation F-actin was diluted 
to 0.65 mg/ml and incubated at 37°C for 15 min with or without a 
final concentration of 0.15 mg/ml of MAP2 in either the presence or 
absence of estramustine or EP. At the end of the incubation period 
aliquots were removed and assayed either for actin binding or actin 
crosslinking studies. 
For the actin binding studies the samples were centrifuged at 37CC 
for 25 min at lOOOOOXg in a TL-100 centrifuge (Beckman Instru-
ments Ltd., Toronto, Ontario). The protein in the pellet was fraction-
ated by SDS-PAGE and stained with Coomassie blue R-250 [20]. For 
crosslinking studies the absorbance at 340 nm was determined using a 
Titertek Multiskan MCC/340 microtiter plate reader. Aliquots were 
also sedimented by centrifugation at 30000Xg in a TL-100 centrifuge 
as described by Pedrotti et al. [20]. 
3. Results 
The effect of estramustine and EP on MAP2: F-actin inter-
action was examined using the sedimentation assay. MAP2 
was therefore incubated either in the absence of F-actin (con-
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trol) or with F-actin either in the absence of drug or in the 
presence of 100 uJVI estramustine or 400 uM EP. At the end of 
the incubation time, the samples were centrifuged at high 
speed (lOOOOOXg for 25 min) and the pellets analysed by 
SDS-PAGE. Significant amounts of MAP2 were observed to 
co-sediment with F-actin (Fig. 1, lane 3), but not in the con-
trol sample in the absence of F-actin (not shown). Similarly, 
MAP2 was also observed to co-sediment with F-actin incu-
bated in the presence of estramustine (Fig. 1, lane 2), suggest-
ing that estramustine does not affect MAP2:actin interaction. 
By contrast, MAP2 failed to sediment when incubated with 
actin filaments in the presence of EP (Fig. 1, lane 1) indicating 
that the phosphorylated analogue affects the MAP2: actin in-
teraction. 
The effect of EP on F-actin :MAP2 interaction was there-
fore further examined at different concentrations of EP using 
the sedimentation assay. As shown in Fig. 2A, the amount of 
MAP2 which co-sedimented with F-actin, while unaffected at 
low concentrations of EP, was gradually reduced as the EP 
concentration increased. The dose-dependent inhibition by EP 
exhibits an IC50, i.e. the amount which inhibits the interaction 
by 50%, of about 180 uM with complete inhibition observed 
at about 240 uM EP. This inhibition cannot be attributed to 
an effect of EP on actin as similar amounts of F-actin were 
pelleted when G-actin was polymerised in either the absence 
or presence of either estramustine or EP (Fig. 2B). 
As MAP2 is also an actin crosslinking protein, we have 
additionally investigated the effect of EP on MAP2-induced 
actin crosslinking. Formation of filament networks leads to 
light scattering and can be monitored by the change in ab-
sorbance at 340 nm (Fig. 3). The absorbance of either F-actin 
or MAP2 alone was low and did not change during incuba-
tion at 30°C, and represented the background, while the co-
incubation of F-actin with MAP2 (molar ratio MAP2: actin of 
Fig. 1. Effect of estramustine and EP on MAP2: actin interaction. 
F-Actin was incubated with MAP2 either in the presence of 400 um 
EP (lane 1) or 100 um estramustine (lane 2) or in the absence of 
drug (lane 3). After centrifugation the pellets were resuspended and 
fractionated by SDS-PAGE on 4-15% acrylamide gradient gels. The 
gels were stained with Coomassie blue; the positions of MAP2 and 
actin are indicated. 
Fig. 2. Effect of increasing concentrations of EP on MAP2: actin in-
teraction (A) and actin polymerisation (B). (A) MAP2 was incu-
bated with F-actin either in the presence of increasing concentration 
of EP or in the absence of drug. After centrifugation the pellets 
were analysed by SDS-PAGE (see Fig. 1) and the recovery of 
MAP2 is shown. Lanes: 1, 300 urn EP; 2, 240 urn EP; 3, 180 urn 
EP; 4, 120 urn EP; 5, 60 um EP; 6, control in the absence of EP. 
(B) G-Actin was polymerised at 30°C for 25 min in the presence of 
different concentrations of EP. At the end of the incubation period 
F-actin was sedimented by centrifugation and the pellets analysed 
by SDS-PAGE and the recovery of actin is shown. Lanes: 1, 400 
um EP; 2, 300 urn EP; 3, 200 um EP; 4, 100 urn EP; 5, control in 
the absence of EP. 
1:20 used) for 15 min at 30°C resulted in an increase in ab-
sorbance at 340 nm (Fig. 3a), and represented the signal. F-
Actin was therefore incubated for 15 min at 30°C with various 
concentrations of EP in either the presence or absence of 
MAP2 and the absorbance change at 340 nm was determined 
at end of the incubation period. The absorbance at 340 nm, 
corrected for the specific absorbance of EP and MAP2, was 
plotted vs. the initial EP concentration. In the presence of 
increasing EP concentrations, the maximal signal observed 
with MAP2 and F-actin was gradually reduced until it 
achieved background levels in the presence of 180 uM EP 
(Fig. 3b). Aliquots were also removed and centrifuged at 
low speed (30000Xg for 40 min) through a 30% sucrose 
cushion and pelleted protein was fractionated by SDS-
PAGE. As shown in Fig. 4, while only a small amount of 
actin was recovered in the pellet when F-actin alone was in-
cubated, the amount of pelleted actin was substantially in-
creased after addition of MAP2, and MAP2 was co-sedi-
mented with the gelled actin (Fig. 4, lanes 1,3). On the 
other hand, the amount of actin which pelleted in the presence 
of 180 uM EP was similar to that of F-actin incubated in the 
absence of MAP2. Moreover, unlike the cross-linked samples 
only trace amounts of MAP2 could be detected in the pellets 
(Fig. 4, lane 2), confirming the complete disruption of micro-
filament networks in these conditions. 
4. Discussion 
EP interacts with MAP2 at the C-terminal region contain-
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Fig 3 MAP2-induced crosslinking of F-actin (a) and the effect of EP on crosslinking (b). (a) The absorbance of F-actin or MAP2 or MAP2 
and F-actin was determined at 340 nm using a microtiter plate reader. A change in the absorbance was observed upon crosslinking of F-actin 
when incubated for 15 min in the presence of MAP2. (b) The effect of EP on MAP2-induced crosslinking was determined and plotted as a 
function of EP concentration. 
ing the microtubule binding domain to inhibit the association 
of MAP2 with microtubules and to induce microtubule depo-
lymerization [8,9]. However, MAP2 also binds and crosslinks 
actin filaments but, to the best of our knowledge, the effect of 
EP on MAP2: actin interaction has not been examined and 
this paper represents the first such study. 
Our data suggest that EP affects the binding of MAP2 to 
actin filaments and induces the disruption of microfilament 
networks. A drug concentration of 240 uM is necessary to 
inhibit MAP2: actin binding while a concentration of 180 
uM is sufficient to inhibit completely the crosslinking activity. 
This difference is probably due to the number of multiple 
interactions required to form a gelled network when com-
pared with a single site for binding. By contrast, estramustine 
does not inhibit MAP2: actin binding (no effect was observed 
even at 200^100 uM estramustine, although at these concen-
trations the drug tended to precipitate), suggesting that it 
should not disrupt the microfilament networks. 
The effect of EP is exerted most probably only through 
binding to the MAP2 molecule as it has no detectable effect 
on G-actin polymerisation. The relatively high drug concen-
trations necessary to induce the described effects are in agree-
ment with the observation that MAP2 can bind 5-6 mol/mol 
EP [18]. The drug concentrations required to disrupt 
MAP2: actin interactions when compared with MAP2: micro-
tubule interactions are somewhat lower in the case of the 
former interaction. 
Considering that (a) EP binds to the MAP2 C-terminal 
microtubule binding domain [7,8,18], (b) MAP2:tubulin inter-
action involves charged domains of the two proteins [21], 
(c) the effect of monovalent and divalent cations suggests a 
similar electrostatic screening interaction for the MAP2:tubu-
lin to that for the MAP2:actin complexes [13], (d) MAP2 
microtubule binding domain also binds to G-actin [14], and 
(e) MAP2 binding sites on tubulin and actin molecules display 
a rather high degree of homology being both rich in charged 
amino acids [14], we suggest that the negatively charged EP 
molecule binds to the positively charged tubulin/actin binding 
Fig. 4. Effect of EP on actin crosslinking. F-Actin was incubated ei-
ther with MAP2 (lane 1) or with MAP2 in the presence of 180 um 
EP (lane 2) or in the absence of MAP2 (lane 3) and sedimented by 
centrifugation through a sucrose cushion. The pellets were analysed 
by SDS-PAGE, the positions of MAP2 and actin are indicated. 
126 
domain of M A P 2 producing its effect both on microtubules 
and actin filaments. This hypothesis is supported by the ob-
servation that under our experimental conditions estramustine 
does not affect M A P 2 : actin interaction, even at high concen-
trations, and that the effect of estramustine derivatives on 
microtubule assembly depends on the charge of the substitu-
ent [7]. 
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